08:05 AM EDT, 09/30/2024 (MT Newswires) -- Moderna ( MRNA ) said Monday that it has dosed the first participant in the US while global recruitment has started for a pivotal phase 3 study evaluating mRNA-1403, an investigational norovirus vaccine.

The trial aims to enroll about 25,000 participants aged 18 years and older globally to assess the vaccine candidate's efficacy and safety in protecting against moderate to severe norovirus acute gastroenteritis in adults, the company said.

Price: 65.98, Change: +0.23, Percent Change: +0.35